Nautilus Biotechnology, Inc.

NASDAQ:NAUT

Biotechnology

Healthcare
$2.43 +2.06%

+$0.05 today

Market cap
$309.51M
Beta
0.75
P/E (TTM)
-4.9
EPS (TTM)
-$0.45
52W Low $0.62High $4.31

Volume 4.55M

Average 0.40M

NAUT Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Nautilus Biotechnology, Inc.NASDAQ: NAUT

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital growth accelerates

Q1 FY2026 change in working capital of $1.17M (cash outflow) rose 103.6% year over year, ahead of the -8.0% change in trailing-twelve-month change in working capital. Sequentially, it fell 22.8% from the prior quarter. Over 3 fiscal years it compounded at +65.7% a year.

Context

  • Change in working capital grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +103.6% holds above the trailing-twelve-month pace of -8.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.17M-22.8% QoQ
Last fiscal yearDec 2025
-$3.58M-34.3% YoY
LTMMar 2026
-$4.18M-8.0% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+103.6%——
1 year-34.3%——
3-year CAGR+65.7%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(3.58M) USD
Year-over-year change
+34.3%

Change in Working Capital vs competitors

How NAUT compares with its peers on the latest reported figures

  • NAUT's LTM Mar 2026 change in working capital of $4.18M is the 7th largest of the 11 companies compared; the peer median is $4.83M.
  • Its year-over-year change of -8.0% is the 5th highest of 11, against a peer median of -56.5%.
  • Over three fiscal years its annual growth of +65.7% compares with a peer median of +44.3%.
NAUT Competitors Peer median
Change in Working Capital for NAUT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ASMBAssembly Biosciences, Inc.LTM Mar 2026$36.78M +105.8%+162.3%51.7%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$34.76M +146.8%+80.5%50.2%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$31.04M -3.9%—110.0%
HUMAHumacyte, Inc.LTM Mar 2026$15.14M +208.6%—750.8%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$8.51M -85.7%+46.2%18.8%
ZURAZura Bio LimitedLTM Mar 2026$6.07M -215.8%——
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$4.18M -8.0%+65.7%—
TNYATenaya Therapeutics, Inc.LTM Mar 2026$3.6M -53.4%+42.5%1601.8%
SGMTSagimet Biosciences Inc.LTM Mar 2026$3.42M -181.2%——
PYXSPyxis Oncology, Inc.LTM Mar 2026$2.15M -59.7%-24.4%15.5%
IMRXImmuneering CorporationLTM Mar 2026$1.66M -293.7%+30.6%—
Peer median (excluding NAUT) $4.83M-56.5%+44.3%51.7%

Competitors are the stored peer set for NAUT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(50.32M)(57.92M)(63.68M)(70.78M)(59M)
Depreciation & Amortization2.84M3.42M5.71M6.35M6.47M
Deferred Income Tax00000
Stock-Based Compensation7.93M10.38M12.14M12.7M6.84M
Change in Working Capital(22K)(788K)(3.22M)(5.46M)(3.58M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.26M(561K)393K(578K)(69K)
Other Working Capital(1.28M)(227K)(3.61M)(4.88M)(3.52M)
Other Non-Cash Items320K(890K)(2.66M)(1.96M)(1.42M)
Operating Cash Flow(39.24M)(45.81M)(51.71M)(59.15M)(50.7M)
Capital Expenditures(2.27M)(2.32M)(2.44M)(2.12M)(1.28M)
Acquisitions (Net)00000
Purchases of Investments(221.8M)(186.59M)(112.89M)(86.28M)(72.49M)
Sales of Investments85.1M163.18M71.6M155.41M108.99M
Other Investing Activities000(760K)0
Investing Cash Flow(138.96M)(25.74M)(43.74M)66.25M35.22M
Debt Repayment00000
Common Stock Issued(7.96M)562K368K1.14M214K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities335.41M0000
Financing Cash Flow327.45M562K368K1.14M214K
Effect of Forex Changes00000
Net Change in Cash149.24M(70.98M)(95.08M)8.25M(15.26M)
Free Cash Flow(41.51M)(48.13M)(54.15M)(61.27M)(51.97M)

Nautilus Biotechnology, Inc.

NASDAQ:NAUT

Intrinsic Alpha fair value

Locked

Current Price

$2.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.